Adjuvant T-DM1 vs Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant T-DM1 Versus Trastuzumab in Patients With Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses From KATHERINE
Ann. Oncol 2021 Apr 28;[EPub Ahead of Print], EP Mamounas, M Untch, MS Mano, CS Huang, CE Geyer, G von Minckwitz, N Wolmark, X Pivot, S Kuemmel, MP DiGiovanna, B Kaufman, G Kunz, AK Conlin, JC Alcedo, T Kuehn, I Wapnir, A Fontana, J Hackmann, J Polikoff, M Saghatchian, A Brufsky, Y Yang, M Zimovjanova, T Boulet, H Liu, D Tesarowski, LH Lam, C Song, M Smitt, S LoiblFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.